Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing orally administered antiviral therapies for serious viral diseases. Its lead product candidate is a fixed-dose combination of bemnifosbuvir and ruzasvir for treating chronic hepatitis C virus (HCV) infection. The company targets global HCV patients with a pan-genotypic, protease inhibitor-free regimen designed for improved efficacy, tolerability, and convenience compared to current standards of care.
This description was generated via AI from an annual report. Updated about 1 year ago.